PRN Therapeutics announced the launch of a novel medical food formulated to reduce the risk of and slow the progression to diabetic retinopathy. The new product, n?retin, is a purified triglyceride form (rTG) omega-3 providing 1200 mgs of EPA and DHA in a 1:5 ratio. With over 30 million people in the United States living with diabetes and another 84 million adults that are pre-diabetic, the rate of diabetic retinopathy is growing rapidly. According to The American Diabetes Association, 60% of adults with type II diabetes present with some form of diabetic retinopathy within 20 years from diagnosis. N?retin will be the first non-prescription, evidence-based medical food for this patient population that must be distributed through the recommendation of physicians.
"We are excited to bring this much needed therapeutic solution to the ophthalmic and optometric communities," Ken Krieg, CEO of PRN Therapeutics, said in a company news release. "The launch of n?retin comes at a perfect time for the immense population of aging baby-boomers who are being diagnosed with diabetes. N?retin will provide an essential therapeutic tool for eyecare professionals and physicians seeking to provide intervention to retinopathy among their diabetic patients."
N?retin is supported by significant peer-reviewed research including published studies in Diabetes Care, National Institutes of Health, JAMA Ophthalmology, and Retina.
Dr. Mitchell Fineman, Retina Specialist commented, "n?retin is revolutionary in this space. The clinical data supporting the product and the growing number of patients at risk for diabetic retinopathy make it a valuable addition to current treatment recommendations for a large proportion of diabetic patients."
N?retin is available exclusively through a doctor recommendation and direct delivery by PRN Therapeutics. PRN Therapeutics is currently providing webinars and other educational materials to enable patient access to n?retin and meet the strong demand as quickly as possible.